Sparkle of Hope Founding Chair
Sparkle of Hope Honorary Chair
FRED HASSAN Chairman, Caret Group Director, Warburg Pincus
ROB M. DAVIS Chairman and CEO Merck
Rob Davis is chairman of the board and chief executive officer of Merck. Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and
Fred Hassan is a Director with the private equity firm, Warburg Pincus. He is also a Board member of BridgeBio, EyePoint, Precigen, and Cocrystal Pharma. Fred Hassan is the former Chairman and CEO of Schering-Plough Corporation. Prior to joining Schering-Plough in April 2003, Hassan was Chairman and CEO of Pharmacia Corporation – a company that was formed in March 2000 from the merger of Monsanto and Pharmacia & Upjohn. Hassan joined Pharmacia & Upjohn as CEO in 1997. Previously, Hassan was EVP of Wyeth, with responsibility for its global pharmaceutical and medical products businesses. He was elected to Wyeth’s Board in 1995. Earlier in his career, Hassan spent 17 years with Sandoz Pharmaceuticals (now Novartis) and became CEO of its US division. Hassan received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard. Hassan is a founder or co-founder of three major events every year where the bioscience industry is well represented. These are: the CEOs Forum (since 2013), RDL (Research and Development Leadership Summit) (since 2012), and Sparkle of Hope (since 1998). In 2014, a CNBC panel named Hassan to a list of those who have had the most profound impact on the world of business in the previous quarter century
the company’s chief financial officer. Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021, CEO and a member of the board of directors on July 1, 2021, and chairman of the board on December 1, 2022. Prior to joining Merck, Rob was corporate vice president and president of Baxter’s medical products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company. Rob serves on the board of directors for Duke Energy Corporation, one of America’s largest energy holding companies, and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a member of the Northwestern Law Board at the Northwestern University Pritzker School of Law. He is also a board member of Project HOPE, a nonprofit organization focused on empowering health care workers to deliver expert care when and where it is needed most, and of Catalyst, a global nonprofit that promotes equal access to career opportunities and corporate leadership for women. Rob received his J.D. from the Northwestern University Pritzker School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.
Made with FlippingBook - Online Brochure Maker